Preliminary study on the value of circulating PLGF level in predicting the severity of preeclampsia and evaluating pregnancy outcome

doi:10.11958/20231257

Abstract

Abstract:

Objective To investigate the correlation between the level of circulating placental growth factor (PLGF) and the severity of preeclampsia (PE), maternal and infant outcomes and placental pathology. Methods A total of 159 PE patients were selected as the study subjects and divided into the PE₁ group (62 PE patients with termination of pregnancy < 34 weeks) and the PE₂ group (97 PE patients with termination of pregnancy ≥ 34 weeks) according to the gestational age of pregnancy termination. A total of 107 non-PE patients who gave birth during the same period were selected as the control group. Patients were divided into two groups according to the gestational age of termination: the non-PE₁ group (41 non-PE patients with termination of pregnancy at < 34 weeks) and the non-PE₂ group (66 non-PE patients with termination of pregnancy at ≥34 weeks). General data were collected in each group of pregnant women, including age, body mass index (BMI), admission systolic blood pressure, diastolic blood pressure, 24 h urinary protein quantity, gestational times, presence of FGR and fetal embarrassment. General information of newborns during the operation were collected, for example, whether there was fecal contamination of amniotic fluid, neonatal asphyxia, and days of newborn stayed in NICU. PLGF in venous blood of pregnant women was detected on the day of delivery. The placenta was pathologically detected and scored. After delivery, blood gas of umbilical artery was analyzed, and PH (pH), base surplus (BE), lactic acid (LAC) were recorded. Results There were no significant differences in age, gestational times and delivery times between the PE₁ group and the PE₂ group and the corresponding the non-PE₁group and the non-PE₂ group. BMI was higher in the PE₁ group and the PE₂ group than that in the non-PE₁ group and the non-PE₂ group. PLGF was lower in the PE₁ group and the PE₂ group than that in the non-PE₁ group and the non-PE₂ group, respectively, and PLGF was lower in the PE₁ group than that in the PE₂ group (P<0.05). The 24 h urinary protein quantity, systolic blood pressure, diastolic blood pressure and pathological changes of placenta were higher in the PE₁ group than those in the PE₂ group (P<0.05). There were no significant differences in fecal staining of amniotic fluid, fetal embarrassed condition and pH value of umbilical artery blood gas during delivery between the PE₁ group and the PE₂ group. Compared with the PE₂ group, the proportion of neonatal asphyxia and FGR, the umbilical artery blood gas LAC were increased, the BE value was decreased, and the time of staying in NICU was prolonged in the PE₁ group (P<0.05). Conclusion The level of circulating PLGF is decreased in patients with preeclampsia. PLGF has certain value in evaluating PE and predicting adverse pregnancy outcome.

Key words: placenta growth factor, pregnancy outcome, placenta, pre-eclampsia

CLC Number:

R714.244

Figures/Tables 4

References 15

[1]	GAROVIC V D, WHITE W M, VAUGHAN L, et al. Incidence and long-term outcomes of hypertensive disorders of pregnancy[J]. J Am Coll Cardiol, 2020, 75(18):2323-2334. doi:10.1016/j.jacc.2020.03.028.
[2]	TATEISHI A, OHIRA S, YAMAMOTO Y, et al. Histopathological findings of pregnancy-induced hypertension:histopathology of early-onset type reflects two-stage disorder theory[J]. Virchows Arch, 2018, 472(4):635-642. doi:10.1007/s00428-018-2315-3.
[3]	CHAU K, HENNESSY A, MAKRIS A. Placental growth factor and pre-eclampsia[J]. J Hum Hypertens, 2017, 31(12):782-786. doi:10.1038/jhh.2017.61.
[4]	POON L C, SHENNAN A, HYETT J A, et al. The International Federation of Gynecology and Obstetrics(FIGO)initiative on pre-eclampsia:A pragmatic guide for first-trimester screening and prevention[J]. Int J Gynaecol Obstet, 2019, 146(3):390-391. doi:10.1002/ijgo.12892.
[5]	杨孜. 多因素、多通路、多机制致病解子痫前期综合征制胜真实世界临床实践[J]. 中国实用妇科与产科杂志, 2017, 33(1):45-51.
	YANG Z. Understanding preeclampsia syndrome in multi-factor and multi-mechainism as well as multipath wining the real world clinical practice[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2017, 33(1):45-51. doi:10.19538/j.fk2017010111.
[6]	韩贞艳, 关红琼. 子痫前期患者的胎盘环状RNA表达谱及与病情的相关性[J]. 天津医药, 2023, 51(5):513-517.
	HAN Z Y, GUAN H Q. The expression profile of circular RNA in the placenta of patients with preeclampsia and its correlation with the patient's condition[J]. Tianjin Med J, 2023, 51(5):513-517. doi:10.11958/20221313.
[7]	TRACY T A, MILLER G L. Obstetric problems of the massively obese[J]. Obstet Gynecol, 1969, 33(2):204-208.
[8]	李冠琳, 杨慧霞. 子痫前期的发病机制及亚型分类[J]. 中华围产医学杂志, 2017, 20(12):899-903.
	LI G L, YANG H X. The pathogenesis and subtype classification of preeclampsia[J]. Chinese Journal of Perinatal Medicine, 2017, 20(12):899-903. doi:10.3760/cma.j.issn.1007-9408.2017.12.012.
[9]	殷平珍, 李惠琴, 李新, 等. 体质量指数联合血脂及脂溶性维生素水平对不同类型重度子痫前期的发病预测价值[J]. 中国计划生育和妇产科, 2020, 12(6):74-78.
	YIN P Z, LI H Q, LI X, et al. The predictive value of BMI combined with blood lipid and fat-soluble vitamin levels in the incidence of different types of severe preeclampsia[J]. Chinese Journal of Family Planning & Gynecotokology, 2020, 12(6):74-78. doi:10.3969/j.issn.1674-4020.2020.06.18.
[10]	闵治红, 杜巧玲. 56例子痫前期产妇外周血和胎盘中PLGF和sVEGFR-1的临床意义[J]. 中国计划生育学杂志, 2021, 29(2):350-354.
	MIN Z H, DU Q L. Clinical significance of placental growth factor and soluble vascular endothelial growth factor receptor1 in peripheral blood and placenta of 56 pregnant women with pre-eclampsia[J]. Chinese Journal of Family Planning, 2021, 29(2):350-354. doi:10.3969/j.issn.1004-8189.2021.02.034.
[11]	郭婷婷, 归婧, 李爽, 等. 早发型子痫前期发病的影响因素分析[J]. 中国妇产科临床杂志, 2023, 24(3):231-233.
	GUO T T, GUI J, LI S, et al. Analysis of the influencing factors of early-onset preeclampsia[J]. Chin J Clin Obstet Gynecol, 2023, 24(3):231-233. doi:10.13390/j.issn.1672-1861.2023.03.003.
[12]	赵影庭, 卢海英, 刘玮. 血清PLGF、sFlt-1和sEng水平与妊娠期高血压和子痫前期的严重程度及其不良结局关系[J]. 中国妇幼保健, 2019, 34(12):2714-2716.
	ZHAO Y T, LU H Y, LIU W. Serum levels of PLGF,sFlt-1,and sEng in relation to the severity of gestational hypertension and preeclampsiaAnd its adverse outcome relationship[J]. Maternal and Child Health Care of China, 2019, 34(12):2714-2716. doi:10.7620/zgfybj.j.issn.1001-4411.2019.12.17.
[13]	华绍芳, 李月琴. 早发子痫前期患者血浆胎盘生长因子水平与围生结局的研究[J]. 实用妇产科杂志, 2017, 33(10):768-771.
	HUA S F, LI Y Q. The study on maternal plasma placental growth factor level and the perinatal outcome in early-onset pre-eclampsia patients[J]. Journal of Practical Obstetrics and Gynecology, 2017, 33(10):768-771.
[14]	中华医学会围产医学分会新生儿复苏学组. 新生儿窒息诊断的专家共识[J]. 中华围产医学杂志, 2016, 19(1):3-6.
	Neonatal Resuscitation Subgroup,Chinese Society of Perinatal Medicine,Chinese Medical Association. Expert consensus for diagnosis of neonatal asphyxia[J]. Chinese Journal of Perinatal Medicine, 2016, 19(1):3-6. doi:10.3760/cma.j.issn.1007-9408.2016.01.002.
[15]	TUULI M G, STOUT M J, SHANKS A, et al. Umbilical cord arterial lactate compared with pH for predicting neonatal morbidity at term[J]. Obstet Gynecol, 2014, 124(4):756-761. doi:10.1097/AOG.0000000000000466.

组别	n	年龄/岁	BMI/（kg/m²）	孕次/次	产次/次	血浆PLGF/（ng/L）
非PE₁组	41	30.59±4.59	27.03±3.36	2.00（1.00，3.00）	0.00（0.00，1.00）	311.91（143.10，513.16）
非PE₂组	66	30.59±3.84	26.96±5.20	2.00（1.00，3.25）	0.00（0.00，1.00）	142.60（31.62，365.57）
PE₁组	62	31.53±5.38	30.74±6.75^a	2.00（1.00，3.25）	0.00（0.00，1.00）	18.26（12.79，30.39）^a
PE₂组	97	31.48±4.67	30.83±4.88^b	2.00（1.00，3.00）	0.00（0.00，1.00）	33.02（22.4，77.96）^bc
F或χ²		0.826	33.600^＊＊	2.953	3.972	96.974^＊＊

组别	n	年龄/岁	BMI/（kg/m²）	孕次/次	产次/次	血浆PLGF/（ng/L）
非PE₁组	41	30.59±4.59	27.03±3.36	2.00（1.00，3.00）	0.00（0.00，1.00）	311.91（143.10，513.16）
非PE₂组	66	30.59±3.84	26.96±5.20	2.00（1.00，3.25）	0.00（0.00，1.00）	142.60（31.62，365.57）
PE₁组	62	31.53±5.38	30.74±6.75^a	2.00（1.00，3.25）	0.00（0.00，1.00）	18.26（12.79，30.39）^a
PE₂组	97	31.48±4.67	30.83±4.88^b	2.00（1.00，3.00）	0.00（0.00，1.00）	33.02（22.4，77.96）^bc
F或χ²		0.826	33.600^＊＊	2.953	3.972	96.974^＊＊

组别	n	24 h尿蛋白定量/g	收缩压/mmHg	舒张压/mmHg	胎盘病理/分
PE₁组	62	4.96（1.77，7.40）	160.98±25.64	107.56±14.92	3.00（3.00，4.00）
PE₂组	97	0.57（0.21，1.58）	146.24±15.80	98.63±10.00	0.00（0.00，3.00）
t或Z		6.536^＊＊	4.489^＊＊	4.522^＊＊	4.851^＊＊

组别	n	24 h尿蛋白定量/g	收缩压/mmHg	舒张压/mmHg	胎盘病理/分
PE₁组	62	4.96（1.77，7.40）	160.98±25.64	107.56±14.92	3.00（3.00，4.00）
PE₂组	97	0.57（0.21，1.58）	146.24±15.80	98.63±10.00	0.00（0.00，3.00）
t或Z		6.536^＊＊	4.489^＊＊	4.522^＊＊	4.851^＊＊

组别	n	羊水粪染	胎儿宫内窘迫	新生儿窒息	FGR	入住NICU天数/d
PE₁组	62	14（23.0）	11（18.6）	32（54.2）	25（41.7）	25.0（15.0，40.0）
PE₂组	97	22（22.7）	8（8.2）	11（11.3）	12（12.4）	6.0（4.0，9.0）
χ²或Z		0.002	3.707	33.811^＊＊	17.662^＊＊	8.483^＊＊